S&P 500   0.66 (+14.63%)
DOW   0.66 (+14.63%)
QQQ   265.19 (-1.89%)
AAPL   437.50 (-2.97%)
MSFT   203.38 (-2.34%)
FB   256.13 (-2.61%)
GOOGL   1,480.54 (-1.09%)
AMZN   3,080.67 (-2.14%)
NVDA   434.00 (-2.82%)
CGC   16.95 (-5.47%)
BABA   248.42 (+0.12%)
TSLA   1,374.39 (-3.11%)
GE   6.73 (+0.90%)
MU   47.76 (-2.83%)
AMD   76.88 (-6.52%)
T   30.20 (-0.03%)
F   7.23 (+1.97%)
ACB   10.02 (-1.96%)
GILD   68.10 (-0.60%)
NFLX   466.93 (-3.40%)
DIS   130.49 (+1.32%)
BAC   26.92 (+1.36%)
BA   180.13 (+0.40%)
S&P 500   0.66 (+14.63%)
DOW   0.66 (+14.63%)
QQQ   265.19 (-1.89%)
AAPL   437.50 (-2.97%)
MSFT   203.38 (-2.34%)
FB   256.13 (-2.61%)
GOOGL   1,480.54 (-1.09%)
AMZN   3,080.67 (-2.14%)
NVDA   434.00 (-2.82%)
CGC   16.95 (-5.47%)
BABA   248.42 (+0.12%)
TSLA   1,374.39 (-3.11%)
GE   6.73 (+0.90%)
MU   47.76 (-2.83%)
AMD   76.88 (-6.52%)
T   30.20 (-0.03%)
F   7.23 (+1.97%)
ACB   10.02 (-1.96%)
GILD   68.10 (-0.60%)
NFLX   466.93 (-3.40%)
DIS   130.49 (+1.32%)
BAC   26.92 (+1.36%)
BA   180.13 (+0.40%)
S&P 500   0.66 (+14.63%)
DOW   0.66 (+14.63%)
QQQ   265.19 (-1.89%)
AAPL   437.50 (-2.97%)
MSFT   203.38 (-2.34%)
FB   256.13 (-2.61%)
GOOGL   1,480.54 (-1.09%)
AMZN   3,080.67 (-2.14%)
NVDA   434.00 (-2.82%)
CGC   16.95 (-5.47%)
BABA   248.42 (+0.12%)
TSLA   1,374.39 (-3.11%)
GE   6.73 (+0.90%)
MU   47.76 (-2.83%)
AMD   76.88 (-6.52%)
T   30.20 (-0.03%)
F   7.23 (+1.97%)
ACB   10.02 (-1.96%)
GILD   68.10 (-0.60%)
NFLX   466.93 (-3.40%)
DIS   130.49 (+1.32%)
BAC   26.92 (+1.36%)
BA   180.13 (+0.40%)
S&P 500   0.66 (+14.63%)
DOW   0.66 (+14.63%)
QQQ   265.19 (-1.89%)
AAPL   437.50 (-2.97%)
MSFT   203.38 (-2.34%)
FB   256.13 (-2.61%)
GOOGL   1,480.54 (-1.09%)
AMZN   3,080.67 (-2.14%)
NVDA   434.00 (-2.82%)
CGC   16.95 (-5.47%)
BABA   248.42 (+0.12%)
TSLA   1,374.39 (-3.11%)
GE   6.73 (+0.90%)
MU   47.76 (-2.83%)
AMD   76.88 (-6.52%)
T   30.20 (-0.03%)
F   7.23 (+1.97%)
ACB   10.02 (-1.96%)
GILD   68.10 (-0.60%)
NFLX   466.93 (-3.40%)
DIS   130.49 (+1.32%)
BAC   26.92 (+1.36%)
BA   180.13 (+0.40%)
Log in

OTCMKTS:MYMXMymetics Stock Price, Forecast & News

$0.05
+0.01 (+17.78 %)
(As of 08/11/2020 04:00 PM ET)
Add
Compare
Today's Range
$0.05
Now: $0.05
$0.06
50-Day Range
$0.04
MA: $0.05
$0.05
52-Week Range
$0.02
Now: $0.05
$0.07
Volume197,677 shs
Average Volume116,390 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
Beta-0.22
Mymetics Corporation, a vaccine company, focuses on developing vaccines for infectious diseases primarily in Switzerland. The company's product pipeline includes vaccine candidates, such as HIV-1/AIDS, intra nasal influenza, malaria, chikungunya, herpes simplex virus, and the respiratory syncitial virus (RSV) vaccine. It has a collaboration agreement with Texas Biomedical Research Institute; PATH Malaria Vaccine Initiative; the Laboratory of Malaria Immunology and Vaccinology of the National Institute of Allergy and Infectious Diseases to develop and produce virosome based vaccine formulations for a malaria transmission-blocking vaccine candidate; RSV Corporation for developing the RSV vaccine; and Sanofi Pasteur Biologics, LLC to investigate the immunogenicity of influenza vaccines. The company was formerly known as ICHOR Corporation and changed its name to Mymetics Corporation in July 2001. Mymetics Corporation was founded in 1990 and is based in Epalinges, Switzerland.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.66 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:MYMX
CUSIPN/A
Phone41-21-653-4535

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$730,000.00
Book Value($0.18) per share

Profitability

Net Income$-4,690,000.00
Net Margins-613.29%

Miscellaneous

Employees8
Next Earnings Date8/11/2020 (Estimated)
OptionableNot Optionable
$0.05
+0.01 (+17.78 %)
(As of 08/11/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive MYMX News and Ratings via Email

Sign-up to receive the latest news and ratings for MYMX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Mymetics (OTCMKTS:MYMX) Frequently Asked Questions

How has Mymetics' stock been impacted by COVID-19 (Coronavirus)?

Mymetics' stock was trading at $0.0379 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, MYMX stock has increased by 39.8% and is now trading at $0.0530.
View which stocks have been most impacted by Coronavirus
.

When is Mymetics' next earnings date?

Mymetics is scheduled to release its next quarterly earnings announcement on Tuesday, August 11th 2020.
View our earnings forecast for Mymetics
.

Has Mymetics been receiving favorable news coverage?

Press coverage about MYMX stock has been trending negative recently, InfoTrie Sentiment reports. InfoTrie rates the sentiment of news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Mymetics earned a media sentiment score of -2.1 on InfoTrie's scale. They also gave news articles about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the stock's share price in the near term.
View the latest news about Mymetics
.

Are investors shorting Mymetics?

Mymetics saw a increase in short interest in February. As of February 28th, there was short interest totaling 20,100 shares, an increase of 20,000.0% from the February 13th total of 100 shares. Based on an average trading volume of 181,200 shares, the days-to-cover ratio is presently 0.1 days.
View Mymetics' Short Interest
.

Who are some of Mymetics' key competitors?

What other stocks do shareholders of Mymetics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Mymetics investors own include Genocea Biosciences (GNCA), Fujitsu (FJTSY), Maxar Technologies (MAXR), Q BioMed (QBIO), Revance Therapeutics (RVNC), Boeing (BA), Activision Blizzard (ATVI), Asure Software (ASUR), Arlo Technologies (ARLO) and Appian (APPN).

Who are Mymetics' key executives?

Mymetics' management team includes the following people:
  • Mr. Ronald Kempers, CEO, Pres & CFO (Age 51)
  • Dr. Sylvain Fleury, Chief Scientific Officer (Age 57)
  • Mr. Anthony Jessop, Sr. VP (Age 78)
  • Dr. Antonius Johannes Stegmann, Head of R&D and Chief Scientific Officer of Mymetics BV
  • Mr. Mario Amacker Ph.D., Head of Quality & Manufacturing

What is Mymetics' stock symbol?

Mymetics trades on the OTCMKTS under the ticker symbol "MYMX."

How do I buy shares of Mymetics?

Shares of MYMX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Mymetics' stock price today?

One share of MYMX stock can currently be purchased for approximately $0.05.

What is Mymetics' official website?

The official website for Mymetics is www.mymetics.com.

How can I contact Mymetics?

Mymetics' mailing address is Route de la Corniche 4, Epalinges V8, CH-1066. The company can be reached via phone at 41-21-653-4535 or via email at [email protected]

This page was last updated on 8/11/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.